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Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder characterized by amyloid accumulation, neuronal death,
and cognitive impairments. Yi-Chi-Tsung-Ming-Tang (YCTMT) is a traditional Chinese medicine and has never been used to
enhance cognitive function and treat neurodegenerative disorders such as senile dementia. Whether YCTMT has a beneﬁcial role
in improving learning and memory in AD patients remains unclear. The present study showed that oral administration of YCTMT
ameliorated amyloid-β-( A β1−40) injection-induced learning and memory impairments in rats, examined using passive avoidance
and Morris water-maze tests. Immunostaining and Western Blot results showed that continuous Aβ1−40 infusion caused amyloid
accumulation and decreased acetylcholine level in hippocampus. Oral administration of medium and high dose of YCTMT 7
days after the Aβ1−40 infusion decreased amyloid accumulation area and reversed acetylcholine decline in the Aβ1−40-injected
hippocampus, suggesting that YCTMT might inhibit Aβ plague accumulation and rescue reduced acetylcholine expression. This
study has provided evidence on the beneﬁcial role of YCTMT in ameliorating amyloid-induced AD-like symptom, indicating that
YCTMT may oﬀer an alternative strategy for treating AD.
1.Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that gradually impairs memory and cognition [1].
It has been estimated that about 5% of the population older
t h a n6 5y e a r si sa ﬀected by AD [2]. The incidence of AD
doubles every 5 years and 1275 new cases diagnosed yearly
per 100,000 persons older than 65 [3]. In 2010, the number
of worldwide AD patients has reached 35 million [4, 5]. The
high cost spending on AD treatment and patient care makes
AD become one of the most challenging brain disorders in
elder human and causes tremendous ﬁnancial burden.
AD is characterized by cognitive impairment, memory
loss, dementia in neuropsychology, and intracellular neu-
roﬁbrillary tangles and senile plaques in histopathology [6,
7]. During the progress of AD, short-term memory is ﬁrst
aﬀectedduetoneuronaldysfunctionanddegenerationinthe
hippocampus and amygdala. The pathogenic mechanisms of
AD include impaired cholinergic function, increased oxida-
tive stress, induction of the amyloid cascade (i.e., amyloid2 Evidence-Based Complementary and Alternative Medicine
beta, Aβ, deposition, and plaque formation), expression of
inﬂammatory mediators, deﬁciencies in steroid hormones,
and appearance of glutamate-mediated excitotoxicity [2].
The amyloid cascade hypothesis, which suggests a pivotal
role for Aβ in the pathogenesis of AD, is accepted by most
investigators in this ﬁeld [8]. Aβ is the major component
of the senile plaques [9–11], and extensive studies have
indicatedthatAβpeptidescontributetotheneuronalcellloss
and pathogenesis of AD [12, 13].
Aβ1−40 is a prone-to-aggregation product of amyloid
precursor protein (APP) proteolytic cleavage [14, 15]a n d
has been shown to have a toxic eﬀect on endothelial
c e l l si nc e r e b r a lc i r c u l a t i o ni nv i t r o[ 16]. Direct injection
of synthetic Aβ1−40 into particular brain regions has been
used to induce AD-like pathological changes in animal
model [17]. Recently, Passos and colleagues described a
mouse model of acute inﬂammation induced by Aβ1−40
intracerebroventricular injection that appears to mimic the
early phase of AD progression [18, 19]. Increased oxidative
stress owning to lipid peroxidation, protein oxidation, and
hydrogen peroxide formation may also be involved in Aβ-
induced neurotoxicity [20]. Indeed, antioxidant therapy
prevents the learning and memory deﬁcits induced by Aβ in
rats [21], and it also delays the clinical progression of the
disease in humans [22]. Proteomic analysis using peptide
mass ﬁngerprint (PMF) has also revealed Aβ1−40-induced
changes in protein expression in the rat hippocampus
[23].
Acetylcholine (Ach), a neurotransmitter of cholinergic
system, inﬂuences neuron plasticity and plays an important
role in cognition and memory [24, 25]. Aβ deposition
is closely associated with dysfunction and degeneration of
cholinergic neuronal circuits in the basal forebrain nuclei
and also results in deﬁcit of Ach in cortical and hippocampal
areas[26].Consistently,upregulationofacetylcholinesterase,
an enzyme that catalyzes the hydrolysis of Ach, has been
reported within and around amyloid plaques [27], and
upregulation of its activity has also been shown to encourage
the assembly of Aβ into ﬁbrils that lead to Aβ toxicity [28].
The level of Ach has also been shown to be related to the
degree of amnesia and Aβ depositions in the AD brain [29].
All these studies suggest that Ach plays an important role in
AD [30, 31].
Whileuptonowtherehasbeennoeﬀectivetreatmentfor
AD, targeting Aβ production and reversing Ach diminution
are attractive therapeutic strategies for AD [32, 33]. In addi-
tion, alternative medicines that improve AD symptom have
also been recently identiﬁed and they are natural and may
be safer and more eﬀective than currently commercialized
drugs for AD [32, 33] .Y C T M Tw a sﬁ r s ti n t r o d u c e db ya n
ancient Chinese physician, Dong-Yuan Li, in Jin Dynasty
(AD 1200s). YCTMT is a decoction made of various Chinese
herbs including Astragali radix, Ginseng radix, Puerariae
radix, Paeoniae lactiforae, Phellodendri contex, Viticis fructus,
Cimicifugae uralensis,a n dGlycyrrhiza uralensis. Ginseng
can reduce oxidative stress that damages neuroplasticity,
neurogenesis, and memory formation [34, 35]. In addi-
tion, Ginseng has also been shown to promote axonal
and dendritic extension [36]. Astragalus promotes axonal
m a t u ra ti o na n dp r ev e n t sm e m o ryl o s si nm i c e[37]. Puerarin
and Glycyrrhiza have been shown to have neuroprotective
eﬀects against Aβ treatment in mouse model [38, 39].
According to the theory of Dr. Li, Yi-Chi-Tsung-Ming-Tang
(YCTMT, also known as Yiqicongming decoction) treats or
prevents dizziness, tinnitus, and blurred vision. Therefore, it
is intriguing to know whether YCTMT also has a beneﬁcial
eﬀect on ameliorating AD-related symptoms. The aim of
this study was to evaluate the eﬀect of YCTMT treatment on
Aβ1−40-induced AD-like symptoms and possible underlying
mechanism.
2.MaterialsandMethods
2.1. Drugs and Reagents. YCTMT is composed of Astragali
radix, Ginseng radix, Puerariae radix, Paeoniae lactiforae,
Phellodendri contex, Viticis fructus, Cimicifugae uralensis,a n d
Glycyrrhiza uralensis inaratioof5:5:5:1:1:1.5:3:5(dry
weight). All components were purchased from a Chinese
herbal shop in Taichung city, Taiwan, and conﬁrmed by
Professor Ming-Tsuen Hsieh. YCTMT (0.5kg) was prepared
as a mixture of all above components and extracted with 5L
distilled water at 100◦C. The liquid extract was powdered
by heating in a rotary vacuum evaporator. In the study,
YCTMT powder was dissolved in distilled water to make the
ﬁnal concentrations at 0.5, 1.0, and 2.0g/mL. Aβ1−40 was
purchased from Tocris Bioscience (Ellisville, MO, USA) and
dissolved in a vehicle containing 35% acetonitrile and 0.1%
triﬂuoroacetic acid. Other chemicals were purchased from
Sigma-Aldrich (St Louis, MO, USA).
2.2. Animals. Adult male Sprague-Dawley (S.D.) rats (200–
250g) were purchased from BioLASCO (Taipei, Taiwan).
The rats were maintained on a standard diet with water
ad libitum and housed under a 12:12 light-dark cycle
in a temperature-controlled environment (23 ± 1◦C). The
animals were cared in accordance with guidelines provided
by the Institutional Animal Ethics Committee of China
Medical University (Taichung, Taiwan).
2.3. Rat Model with AD-Like Phenotype. Rat model with
AD-like phenotype was developed by infusing Aβ1−40 into
cerebral ventricle in the brain as described previously [18,
19, 40]. Brieﬂy, one week before experiment, animals were
randomly divided into ﬁve groups (n = 9f o re a c hgr o u p ) .A t
day 0, rats were anaesthetized with phenobarbital (45mg/kg,
i.p.), placed in a Narishige stereotaxic instrument with the
head being ﬁxed. The skull was opened carefully, and a
cannulawasimplantedintotherightventricleatcoordinates:
A − 1.4, L ± 2.4, and V 7.2, using an atlas [41]. At
day 1, vehicle or Aβ1−40 was continuously administered
(25pM/day) intraventricularly at an infusion rate of 0.5μL/h
for three weeks via the cannula that was powered by a
miniosmotic pump (model 2002, Alzet, CA, USA). The
control rats were infused with the vehicle only. From the 8th
day, rats were fed with YCTMT (0.5, 1.0, and 2.0g/kg/day)
orally once a day. The experimental scheme was presented in
Figure 1.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Experimental scheme.
2.4. Passive Avoidance Test. The passive avoidance test was
performed at day 15 and 16 after surgery according to
step-through passive avoidance task previously described
[42]. Brieﬂy, the guillotine door connecting the light and
dark space was closed during the trial training. When a
rat was placed in the light space, with its back facing the
guillotine door, the door was opened. The time of step-
throughlatency(STL)takenbytherattoenterthelightspace
was measured with a stopwatch. Once the rat entered the
dark space, the door was closed. An inescapable scrambled
foot-shock (1.0mA for 2s) was then delivered through the
grid ﬂoor. The rat was removed from the dark space 5
seconds after the shock was administered. Then, the rat was
put back into the home cage until the retention trial was
over.
2.5. Morris Water-Maze Test. A Morris water-maze test was
used in the study to assess the memory capability [43, 44].
In brief, the apparatus consisted of a circular water tank
(180cm in diameter, 60cm in height, ﬁlled with water in
a depth of 50cm, at 28 ± 1◦C) with a platform (11cm
in diameter) set under the water. Morris water-maze is a
swimming-based model in which animals must learn to
escape from water and step onto the platform. An escape
platform was placed in a constant position in the center
of one of the four quadrants of the tank and 1cm below
the water surface. For reference memory test, the rats were
trained for 3 days (starting from day 17 to 19), 120s per
trial, and 4 trials per day starting at four diﬀerent positions
with 30min intervals (Figure 1). If the rats could not ﬁnd
the hidden platform within each training session (120s), the
animals were led to it. If the rats swam onto the platform
within 120s, the rat was allowed to stay on the platform for
30s then returned to home cage. In each training session, the
latencyto escape onto the hidden platformwas recorded. For
probememorytest,thehiddenplatformwasremovedonday
20, and memory retrieval was examined by a probe trail that
lasted for 120s in the pool. The time at which the animals
crossed the annulus where the platform had been located
was assigned. Twenty-four hours after probe trial, working
memory (reacquisition) test was performed by measuring
the time each rat spent in the new quadrant of the target
platform.
2.6. Immunohistochemical Detection for Aβ and Ach Expres-
sion in Brain. Rats were sacriﬁced at day 21 with pentobar-
bital (90mg/kg, i.p.) and perfused transcardially with saline,
followed by 4% paraformaldehyde in saline. After postﬁxa-
tion, the whole brain was removed and prepared for paraﬃn
slice. Brain sections with 5μm thickness were obtained on a
microtome (Leica 2030 Biocut) at 1-mm interval from the
stereotaxic coordinates between −1.46mm and −3.40mm
Bregma. Brain sections were deparaﬃnized in xylene, rehy-
drated in a series of ethanol, and endogenous peroxidase
quenched with 1% (v/v) H2O2 in methanol and microwaved
for 15min (with 650W) in 0.01M citrate buﬀer (pH 6.0).
Nonspeciﬁc binding sites were blocked by blocking buﬀer
containing 10% (v/v) goat normal serum and 0.1% Triton
X-100 in PBS for 60min at room temperature. Antibodies
against Aβ (1:300 dilution, Convance, no. SIG-39220) and
Ach (1:300 dilution, Chemicon, Billerica, MA, USA) were
applied to sections overnight at 4◦C. Sections were washed
with PBS, incubated with biotinylated secondary antibody
for 2hr at 25◦C, washed, and placed in avidin-peroxidase
conjugate solution for 1hr. The horseradish peroxidase
reaction was detected with 0.05% diaminobenzidine and
0.03% H2O2. The reaction was stopped with H2O, and
sections were dehydrated in an ethanol series, cleared in
xylene, and coverslipped in permanent mounting solution.
Protein expression area in each brain section was measured
according to Lim et al. [45] and Liao et al. [46] with slight
modiﬁcation. Brieﬂy, a full brain middle section area was
measured by an image analyzer (Leica, Q500MC, Nussloch,
Germany). Brain sections of each rat group were measured
under 40x magniﬁcation, and at least 20 ﬁelds from each
brain section were counted. The permillage of Aβ-o rA c h -
positive areas was calculated using the following equation:
‰of Aβ or Ach area = (sum of Aβ- or Ach-positive area/total
area of brain section) ×1000‰.
2.7. Western Blot. Protein extraction was performed in RIPA
lysis Buﬀer 50mM Tris, pH 7.4, 150mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, protease inhibitor
cocktail (sodium orthovanadate, sodium ﬂuoride, EDTA,
leupeptin), and 1mM PMSF. Quantiﬁcation of protein was
performed using the BCA Protein Assay Kit (Beyotime).
Equal amounts of protein samples were separated on 12%
SDS-PAGE gels and transferred onto a PVDF membrane
at 0.8mA/cm2 for 1.5h. The membrane was blocked with
5% nonfat milk in a 20mM Tris-HCl (pH 7.4) containing
150mM NaCl and 0.05% Tween20 (TBS-T) for 1h at
RT and incubated with the primary antibodies: β-amyloid
antibody (1:1000 dilution, Abcam, Cambridge, MA, USA),
antiacetylcholine (Chemicon, no. MAB5302.), and β-actin
(abs, no. abs-24) at 4◦C overnight. After being washed with
TBS-T, the membrane was incubated with HRP-conjugated
IgG (MILLIPORE, Chemiluminescent HRP Substrate, no.
WBKLS0500) for 1h at RT, washed with TBS-T again,
and detected by ECL (Thermo Scientiﬁc). Densitometric
quantitation was analyzed with FUJIFILM, Multi Gauge
V3.0 Software, and standardized with β-actin. All Western
Blotting samples were run in triplicate.4 Evidence-Based Complementary and Alternative Medicine
2.8. Statistical Analysis. All of the data obtained were
expressed as mean ± standard errors of means (SEM) and
analyzed using one-way analysis of variance (ANOVA),
followed by post hoc between-group analyses using Scheﬀ´ e’s
test for multigroup comparisons. The criterion for statistical
signiﬁcance was P<0.05 in all evaluation.
3. Results
3.1.YCTMTPosttreatmentReversedAβ1−40-MediatedImpair-
ment in Memory Retention. Result from passive avoidance
test showed that at day 15 after Aβ1−40 infusion signiﬁcantly
reduced the step through latency (STL) of treated mice com-
pared to the vehicle injection (P<0.05, Figure 2), suggesting
an Aβ1−40-induced impairment in memory retention after
2-week continuous injection. YCTMT posttreatment for 7
days with doses of 1.0 and 2.0g/kg/day, but not 0.5g/kg/day,
signiﬁcantly attenuated Aβ1−40-mediated reduction in STL
(P<0.05, Figure 2), indicating that YCTMT reversed
Aβ1−40-mediated impairment in a dose-dependent manner.
There was no signiﬁcant diﬀerence between the control and
YCTMT-treated groups at 1.0 and 2.0g/kg/day. This result
suggested that treatment with YCTMT recovered Aβ1−40-
induced deﬁcit in memory retention in rats.
3.2.YCTMTEﬀectivelyReversedAβ1−40-InducedImpairments
in Learning and Memory. To further evaluate the therapeutic
eﬀectofYCTMTonAβ1−40-inducedimpairmentsinlearning
and memory, Morris water maze test was conducted. In
reference memory test, these Aβ1−40-treated animals showed
signiﬁcantly longer escape latency than normal control
animals at day 17, 18, and 19 postinfusion of amyloid
(Figure 3(a)). Posttreatment of YCTMT with the lowest dose
of 0.5g/kg/day showed no eﬀect on Aβ1−40-caused deﬁcits.
However, YCTMT treatment at dose of 1.0g/kg/day signiﬁ-
cantly reduced escape latency in Aβ1−40-treated rats at day 17
and 19, but not at day 18. Posttreatment with 2.0g/kg/day
YCTMT reversed increased escape latency caused by Aβ1−40
injection at all three test days (day 17 to 19), and the
latency reached the level as short as that of normal control.
These results indicated that Aβ1−40-induced impairments in
spatiallearningmemorywerereversedbyposttreatmentwith
YCTMT in a dose-dependent manner.
The beneﬁcial eﬀect of YCTMT on Aβ1−40-induced
learning deﬁcit was further analyzed using probe and work-
ing memory tests. The number of annulus crossing, referred
to the number of passing over the previous platform site, was
measured at day 20. Result showed that number of annulus
crossings in Aβ1−40-treated group was signiﬁcantly lower
than that of control group, whereas YCTMT posttreatment
signiﬁcantly elevated the number in a dose-dependent
manner and showed signiﬁcance at 1.0 and 2.0g/kg/day
(P<0.05, Figure 3(b)). Compared to the control group,
Aβ1−40-treated group also showed signiﬁcantly longer escape
latency to found the platform at a constant location and
to ﬁnd the hidden platform at a new location during the
reference memory test (day 17–19, Figure 3(a)) and during
the working memory test (day 21, Figure 3(c)), respectively,
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Figure 2: Passive avoidance test at day 15 after Aβ1−40 infusion.
Aβ1−40 infusion reduced step-through latency of rats, and it was
restored by YCTMT posttreatment (n = 9 for each group). YCTMT
(0.5, 1.0, and 2.0g/kg/day) was administrated for a week before
test. ∗Represents signiﬁcant diﬀerence between the indicated and
normal control group; #between the indicated and Aβ1−40 group,
P<0.05.
suggesting the Aβ1−40-induced impairments in reference
and working memory in injected rats. Posttreatment with
YCTMT at dose of 1.0 and 2.0g/kg/day signiﬁcantly reversed
Aβ1−40-caused increase of escape latency. These results
again demonstrated that YCTMT was able to ameliorate
Aβ1−40-caused impairment in learning and memory in a
variety of forms.
3.3. YCTMT Signiﬁcantly Decreased Aβ1−40-Induced Aβ
Plaque Area. To investigate the eﬀect of YCTMT post-
treatment on amyloid protein burden in the brain, sec-
tions were analyzed with immunohistochemical staining.
4G8 antibody against amino acid residues 17–24 of beta-
amyloid was used in the study (Figures 4(a)–4(e)). Intracere-
broventricular (i.c.v.) administration of Aβ1−40signiﬁcantly
increased Aβ plaque area (arrow in Figure 4(b)) in hip-
pocampus compared with vehicle injection in the control
group (Figure 4(a)). Amyloid accumulation was shown in
brown and located in the hippocampus. Treatment with 1.0
and 2.0g/kg/day YCTMT reduced the amyloid-accumulated
area, showing as decreased size of 4G8-positive area in
hippocampus (Figures 4(d) and 4(e)). Quantitative analysis
showed that YCTMT treatment reduced Aβ plaque area
in hippocampus in a concentration-dependent manner
(Figure 4(f)). This result suggests that the beneﬁcial eﬀect
of YCTMT on Aβ1−40-induced impairment in cognition
might be mediated by reducing Aβ accumulation in the
hippocampus.
3.4.YCTMTSigniﬁcantlyReversedAβ1−40-InducedDecrement
of Ach Area. Ach is an important neurotransmitter andEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: YCTMT posttreatment improved memory of Aβ1−40-infused rat in Morris water-maze test. (a) Reference memory test at day
17–19. (b) Probe test at day 20. (c) Working memory test at day 21. Aβ1−40-infused rats were administrated with YCTMT (0.5, 1.0, and
2.0g/kg/day) before tests. ∗Represents signiﬁcant diﬀerence between the sham and Aβ1−40 on the same day; #is for the comparison between
Aβ1−40 and Aβ1−40 + YCTMT on the same day, P<0.05.
plays critical roles in the formation of learning/memory
and etiology of Alzheimer’s disease [47]. To explore the
possible mechanism of YCTMT-mediated beneﬁcial role
in relieving AD-like symptom, we further evaluated Ach
expression using immunohistochemical analysis (Figure 5)
and Western Blot (Figure 6). Injection of Aβ1−40 signiﬁcantly
decreased Ach expression in hippocampus compared with
the control group (Figures 5(a) and 5(b)). Quantitative data
showed that YCTMT reversed Ach area in a concentration-
dependent manner in the whole brain. Treatment with
1.0 and 2.0g/kg/day YCTMT signiﬁcantly reversed the
expression of Ach in the brain (Figures 5(d) and 5(e)).
YCTMT-inducedreversalofAchexpressionlevelafterAβ1−40
injection wasalsoconﬁrmedwithWesternBlot.Quantitative6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: YCTMT posttreatment decreased Aβ1−40-induced amyloid accumulation. (a) Control. (b) Aβ1−40 infusion (25pmol). (c)–(e)
YCTMT treatment with doses of 0.5, 1.0, and 2.0g/kg/day. (f) Quantiﬁcation of amyloid accumulation area. ∗Represents signiﬁcant
diﬀerence between the indicated and normal control group; #between the indicated and Aβ1−40 group, P<0.05. The scale bar represents
100μm.
result of Western Blot showed that medium- and high-
dose YCTMT treatment rescued reduced Ach expression
(Figure 6(c)), suggesting the beneﬁcial eﬀect of YCTMT on
AD-like symptom. This result suggested that posttreatment
with YCTMT could reverse Aβ1−40-reduced diminish of Ach
expression correlated with functional deﬁcit in the AD brain.
We also found that therewasa correlation between amyl-
oidplaqueareaandacetylcholineexpressionsite(R =0.719).
4. Discussion
In this study, we observed a beneﬁcial eﬀect of YCTMT post-
treatment on Aβ1−40-induced AD-like symptoms. YCTMT
treatment decreased Aβ1−40-induced amyloid burden and
reverseddeclinedAchlevelinhippocampus.Italsoimproved
learning and memory function in treated rats in a dose-
dependent manner. These results provide evidence of theEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: YCTMT posttreatment reversed Aβ1−40-induced decreases of Ach level. (a) Control. (b) Aβ1−40 infusion (25pmol). (c)–(e)
YCTMT treatment with doses of 0.5, 1.0, and 2.0g/kg/day, respectively. (f) Quantiﬁcation of Ach expression. ∗Represents signiﬁcant
diﬀerence between the indicated and normal control group; #between the indicated and Aβ1−40 group, P<0.05. The scale bar represents
100μm.
therapeutic eﬀect of YCTMT on AD and suggest a potential
treatment strategy.
Investigators have established that toxic Aβ is the major
player in neuronal damage and dementia in both in vitro
culture assays and in the intact brain of animal [48]. Notably,
i.c.v. injections of Aβ1−40 into rats produced learning disabil-
ity, brain morphological changes, and cholinergic neuronal
degeneration [49]. In addition, Aβ1−40 induces spatial learn-
ing and spatial working memory deﬁcits in animal model
[50]. In the present study, we conﬁrmed that continuous
infusion of Aβ1−40 into the cerebral ventricle induced
deﬁcitsinmemoryretention,spatiallearningmemory,probe
memory, and working memory in the rats. Moreover, post-
treatment with YCTMT reversed various types of learning8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: YCTMT posttreatment reversed Aβ1−40 and Ach protein level. (a) Comparison of protein level of beta-amyloid and Ach using
Western Blot. (b) Quantiﬁcation of amyloid protein level. (c) Quantiﬁcation of Ach protein level. ∗represents signiﬁcant diﬀerence between
the indicated and normal control group; #between the indicated and Aβ1−40 group, P<0.05.
and memory loss caused by Aβ1−40. These results indicated
that YCTMT might have beneﬁcial anti-Alzheimer’s disease
eﬀects on Aβ1−40-induced AD animal model.
We also found that i.c.v. administration of Aβ1−40-
induced Aβ plague formation was consistent with previous
report [15,18–20,22].BothWBandimmunostainingresults
showedthatposttreatmentwithYCTMTfor7daysdownreg-
ulated Aβ burden in the rat brain. Aβ1−40 contributes to the
progression of AD and directly impairs cholinergic signaling
and Ach release [51]. Activities of choline acetyltransferase
and acetylcholinesterase, one for synthesis and the other for
hydrolysis of acetylcholine, decrease signiﬁcantly and corre-
late with the extent of intellectual impairment in Alzheimer’s
dementia patients [52]. Coincidently, we also found that
posttreatmentwithYCTMTrecoveredtheexpressionsofAch
in the rat brains that were challenged with Aβ1−40. These
results implied that YCTMT might reduce the production
of Aβ plaque, possibly through increasing the expression ofEvidence-Based Complementary and Alternative Medicine 9
Ach. However, the mechanisms underlying the inﬂuence of
Ach expression need further study.
Traditional Chinese Medicine (TCM) has been around
forthousandsofyearsandextensivelyusedintheprevention,
diagnosis, and treatment of diseases in China. There are
several TCMs that have been used to enhance cognitive
function and senile dementia [53]. YCTMT is one of the
TCMs and has been conventionally used in the improvement
of visual acuity and hearing in purpose. Our results provided
new evidence of the beneﬁcial role of YCTMT in AD-
associated learning and memory deﬁcits. Oral administra-
tion of YCTMT in S.D. rats appeared to reverse the Aβ1−40-
impaired memory, spatial learning memory, probe memory,
and working memory deﬁcits. YCTMT might inhibit Aβ
plague accumulation and reverse Ach decline. This study
suggests a potential use of YCTMT as a potential therapeutic
agent for treating AD.
5. Conclusion
We have shown that YCTMT inhibits Aβ plague accumula-
tionandrescuesreducedacetylcholineexpression.Thisstudy
has provided evidence on the beneﬁcial role of YCTMT in
ameliorating amyloid-induced AD-like symptom, indicating
that YCTMT may oﬀer an alternative strategy for treating
AD.
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